NES - nestin Gene
Species: Sus scrofa
Gene Type: protein coding
Gene ID: 100153933
NES Products (1)
| mRNA | Protein | Name |
|---|---|---|
| XM_005663265.3 | XP_005663322.1 | nestin |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
nestin |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(19)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0193A | Prazosin hydrochloride | 99.89% | Unkown | |
| HY-122272 | Paroxetine | 99.66% | Yes | |
| HY-B0492 | Paroxetine hydrochloride | 99.98% | Unkown | |
| HY-B0527 | Amitriptyline | 99.94% | Yes | |
| HY-B0196 | Venlafaxine | Inhibitor | 99.71% | Yes |
| HY-B0527A | Amitriptyline hydrochloride | 99.94% | Yes | |
| HY-17385 | Atomoxetine hydrochloride | Inhibitor | 99.91% | Yes |
| HY-B0196A | Venlafaxine hydrochloride | Inhibitor | 99.58% | Yes |
| HY-B1110 | Nomifensine | Inhibitor | 98.93% | Unkown |
| HY-B1110A | Nomifensine maleate | Inhibitor | 98.73% | Unkown |
| HY-W380450 | Viloxazine | 99.15% | Unkown | |
| HY-125784 | Viloxazine hydrochloride | Inhibitor | 98.94% | Unkown |
| HY-B0527AR | Amitriptyline hydrochloride (Standard) | 99.03% | Unkown | |
| HY-122272R | Paroxetine (Standard) | 99.79% | Unkown | |
| HY-107370 | Atomoxetine | Inhibitor | 98.50% | Yes |
| HY-B0196AR | Venlafaxine hydrochloride (Standard) | Inhibitor | 99.99% | Unkown |
| HY-107370A | (Rac)-Atomoxetine hydrochloride | Control | / | Unkown |
| HY-B0193AR | Prazosin hydrochloride (Standard) | / | Unkown | |
| HY-B0773 | Paroxetine mesylate | / | Unkown |
Clinical Phase
Bioactive Molecules
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-16736A | Centanafadine hydrochloride | Inhibitor | 99.55% | Phase 3 |
| HY-18600 | Azimilide | Inhibitor | 99.01% | Phase 3 |
| HY-18600A | Azimilide dihydrochloride | Inhibitor | 98.17% | Phase 3 |
| HY-119541 | Ampreloxetine | Inhibitor | / | Phase 3 |
| HY-119541A | Ampreloxetine TFA | 98.30% | Phase 3 | |
| HY-16736 | Centanafadine | Inhibitor | 99.62% | Phase 3 |
| HY-106865 | Mivazerol | / | Phase 3 | |
| HY-15651 | Alvelestat | Inhibitor | 99.87% | Phase 2 |
| HY-108039 | Bezisterim | Inhibitor | 95.0% | Phase 2 |
| HY-14472 | Tesofensine | Inhibitor | 99.35% | Phase 2 |
| HY-U00256 | ZD8321 | Inhibitor | ≥95.0% | Phase 2 |
| HY-15793 | NBI-98782 | Inhibitor | 98.56% | Phase 1 |
| HY-101607 | KT-362 | Antagonist | / | Phase 1 |
| HY-123044 | Tedatioxetine | Antagonist | / | Phase 1 |
| HY-145487A | 5-Hydroxy-6-methoxy (S)-duloxetine maleate | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(91)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-101784 | NE 52-QQ57 | 99.80% | Unkown | |
| HY-101484A | NE-100 hydrochloride | 99.1% | Unkown | |
| HY-78932A | Dap-NE hydrochloride | 99.99% | Unkown | |
| HY-N0740 | Jatrorrhizine chloride | Inhibitor | 99.82% | Unkown |
| HY-101323 | Olvanil | Agonist | ≥99.0% | Unkown |
| HY-16011 | NE 10790 | Inhibitor | 99.50% | Unkown |
| HY-78931 | Boc-Dap-NE | 99.96% | Unkown | |
| HY-W008794S | Normetanephrine-d3 hydrochloride | 99.94% | Unkown | |
| HY-N0749A | Jatrorrhizine hydroxide | Inhibitor | 98.06% | Unkown |
| HY-P2922 | Cathepsin C | / | Unkown | |
| HY-W008794 | Normetanephrine hydrochloride | 99.69% | Unkown | |
| HY-B0196S | Venlafaxine-d6 | Inhibitor | 98.55% | Unkown |
| HY-B0527AS | Amitriptyline-d6 hydrochloride | 99.93% | Unkown | |
| HY-78931A | (R,S,S,R,S)-Boc-Dap-NE | 97.13% | Unkown | |
| HY-B0196AS1 | Venlafaxine-d6 hydrochloride | Inhibitor | 98.18% | Unkown |
| HY-132132 | Neutrophil elastase inhibitor 3 | Inhibitor | 97.23% | Unkown |
| HY-78932G | Dap-NE hydrochloride (GMP) | / | Unkown | |
| HY-101755 | Tedatioxetine hydrobromide | Antagonist | 99.83% | Unkown |
| HY-106823 | Tebufelone | Inhibitor | 99.52% | Unkown |
| HY-B0196B | (S)-Venlafaxine | Inhibitor | 98.0% | Unkown |
| HY-N0749 | Jatrorrhizine | Inhibitor | / | Unkown |
| HY-N1745 | 2'-O-Methylisoliquiritigenin | Activator | 99.06% | Unkown |
| HY-W112651 | 2,4,6-Triphenylaniline | Inhibitor | 95.0% | Unkown |
| HY-W417914 | 4-Methylamphetamine hydrochloride | Agonist | 99.86% | Unkown |
| HY-78931B | (S,S,S,S,R)-Boc-Dap-NE | 99.80% | Unkown | |
| HY-78931C | (S,S,R,S,R)-Boc-Dap-NE | 99.78% | Unkown | |
| HY-78931E | (R,S,R,S,R)-Boc-Dap-NE | 98.74% | Unkown | |
| HY-78931F | (R,S,S,S,R)-Boc-Dap-NE | 99.56% | Unkown | |
| HY-78932 | Dap-NE | 99.49% | Unkown | |
| HY-78932C | (2S,3R)-Dap-NE hydrochloride | Inhibitor | / | Unkown |
| HY-W036578 | (E)-3-Chlorocinnamaldehyde | ≥96.0% | Unkown | |
| HY-78931G | Boc-Dap-NE (GMP) | / | Unkown | |
| HY-179566 | CHF-6333 | Inhibitor | / | Unkown |
| HY-15651A | Alvelestat tosylate | Inhibitor | / | Unkown |
| HY-B1110S | Nomifensine-d3 maleate | Inhibitor | / | Unkown |
| HY-101607A | KT-362 free acid | Antagonist | / | Unkown |
| HY-103247 | EMD 66684 | Antagonist | / | Unkown |
| HY-105330 | SIB 1663 | Agonist | / | Unkown |
| HY-107562 | JNJ 10181457 dihydrochloride | Antagonist | / | Unkown |
| HY-11046 | AX-9657 | Inhibitor | / | Unkown |
| HY-111124 | Paroxetine-d2 | / | Unkown | |
| HY-113933 | NE11808 | / | Unkown | |
| HY-118064 | (R)-Thionisoxetine | / | Unkown | |
| HY-118064A | (R)-Thionisoxetine hydrochloride | / | Unkown | |
| HY-122272S2 | Paroxetine-d6-1 | / | Unkown | |
| HY-122300A | Oxaprotiline | Inhibitor | / | Unkown |
| HY-126825 | NE21650 | Inhibitor | / | Unkown |
| HY-12711 | 2-Methoxyidazoxan | Antagonist | / | Unkown |
| HY-129305 | Tampramine fumarate | Inhibitor | / | Unkown |
| HY-129985 | Clovoxamine | Inhibitor | / | Unkown |
| HY-131284 | (S)-Dehydro Venlafaxine | / | Unkown | |
| HY-136860 | (R)-Venlafaxine | Inhibitor | / | Unkown |
| HY-138257 | (S)-Indeloxazine benzenesulfonate | Inhibitor | / | Unkown |
| HY-144246S | Zofenoprilat-NES-d5 | / | Unkown | |
| HY-14472S | Tesofensine-d5 | Inhibitor | / | Unkown |
| HY-14472S1 | Tesofensine-13C,d3 | Inhibitor | / | Unkown |
| HY-17032A | Indeloxazine hydrochloride | Inhibitor | / | Unkown |
| HY-17385S1 | Atomoxetine-d7 hydrochloride | / | Unkown | |
| HY-179566A | CHF-6333 xinafoate | Inhibitor | / | Unkown |
| HY-182465 | CHF-6333 chloride | Inhibitor | / | Unkown |
| HY-182646 | NE-10133 | Inhibitor | / | Unkown |
| HY-18600AS | Azimilide-d8 dihydrochloride | Inhibitor | / | Unkown |
| HY-B0196S1 | Venlafaxine-d6-1 | Inhibitor | 99.9% | Unkown |
| HY-B0196S4 | Venlafaxine-d9 | / | Unkown | |
| HY-N17738 | Acetyljujuboside B | / | Unkown | |
| HY-N6847 | 5,6,7,40-Tetrahydroxyisoflavone-6,7-di-o-b-D-glucopyranoside | / | Unkown | |
| HY-P10435 | KEMPFPKYPVEP | Agonist | / | Unkown |
| HY-P3064 | Scyllatoxin | Antagonist | / | Unkown |
| HY-P3648 | Ala-Ala-Pro-Val-chloromethylketone | Inhibitor | / | Unkown |
| HY-RS09211 | NES Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W061043 | DOV-216,303 | Inhibitor | / | Unkown |
| HY-W681014 | 5-Fluoro-α-methyltryptamine hydrochloride | Activator | / | Unkown |
| HY-W700149 | N,O-Didesmethylvenlafaxine-d3 | / | Unkown | |
| HY-W726472 | N-(E-4-Coumaroyl)-aspartate | / | Unkown | |
| HY-W779743 | NE58043 | / | Unkown | |
| HY-106470 | Difenamizole | / | Unkown | |
| HY-107370S | Atomoxetine-d7 | Inhibitor | / | Unkown |
| HY-107370S1 | Atomoxetine-d5 | / | Unkown | |
| HY-11046A | KRP-109 | / | Unkown | |
| HY-117012 | NE58018 | / | Unkown | |
| HY-122272A | Paroxetine acetate | / | Unkown | |
| HY-122272S | Paroxetine-d4 | / | Unkown | |
| HY-138257A | (R)-Indeloxazine benzenesulfonate | Inhibitor | / | Unkown |
| HY-138818 | N,O-Didesmethylvenlafaxine | / | Unkown | |
| HY-15651R | Alvelestat (Standard) | Inhibitor | / | Unkown |
| HY-78932D | (2R,3R)-Dap-NE hydrochloride | Inhibitor | / | Unkown |
| HY-B0196AS | Venlafaxine-d10 hydrochloride | Inhibitor | / | Unkown |
| HY-B0196S2 | Venlafaxine-d4 | Inhibitor | / | Unkown |
| HY-B0196S3 | Venlafaxine-d10 | Inhibitor | / | Unkown |
| HY-RS17729 | Nes Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24194 | Nes Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service